Skip to main content
SpringerLink
Log in

Delamanid – ein neues Tuberkulose-Medikament im Yin und Yang regulatorischer Erfordernisse und zunehmender Medikamentenresistenz

Delamanid – a new antituberculosis medication in Yin and Yang of regulatory requirements and increasing multidrug resistance

  • Journal Club
  • Published:
Der Pneumologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Skrahina A, Hurevich H, Zalutskaya A et al (2013) Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors. Bull World Health Organ 91:36–45

    Article  PubMed Central  PubMed  Google Scholar 

  2. World Health Organization (2011) Guidelines for the programmatic management of drug-resistant tuberculosis 2011 update. World Health Organization Document WHO/HTM/TB/2011 6:1–33

  3. World Health Organization (2013) Global tuberculosis report 2013

  4. FDA Press Release on Situro (2012) http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm333695.htm

  5. Diacon AH, Dawson R, Hanekom M et al (2011) Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis 15:949–954

    Article  CAS  PubMed  Google Scholar 

  6. Matsumoto M, Hashizume H, Tomishige T et al (2006) OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 3:e466

    Article  PubMed Central  PubMed  Google Scholar 

  7. Gler MT, Skripconoka V, Sanchez-Garavito E et al (2012) Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 366:2151–2160

    Article  CAS  PubMed  Google Scholar 

  8. Skripconoka V, Danilovits M, Pehme L et al (2013) Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 41:1393–1400

    Article  PubMed Central  PubMed  Google Scholar 

  9. Lee M, Lee J, Carroll MW et al (2012) Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 367:1508–1518

    Article  CAS  PubMed  Google Scholar 

  10. World Health Organization (2013) The use of bedaquiline in the treatment of multidrug resistant tuberculosis. Interim policy guidance. http://apps.who.int/iris/bitstream/10665/84879/1/9789241505482_eng.pdf

  11. Diacon AH, Dawson R, Groote-Bidlingmaier F von et al (2012) 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacine combinations: a randomised trial. Lancet 380:986–993

    Article  CAS  PubMed  Google Scholar 

  12. Working group on new TB- drugs (2013) Drug pipeline. http://www.newtbdrugs.org/pipeline.php

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. G. Günther gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Medizinische Klinik, Forschungszentrum Borstel, Parkallee 35, 23845, Borstel, Deutschland

    G. Günther MPH

Authors
  1. G. Günther MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Günther MPH.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Günther MPH, G. Delamanid – ein neues Tuberkulose-Medikament im Yin und Yang regulatorischer Erfordernisse und zunehmender Medikamentenresistenz. Pneumologe 11, 144–147 (2014). https://doi.org/10.1007/s10405-013-0745-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10405-013-0745-9

Search

Navigation